Log In
BCIQ
Print this Print this
 

JNJ-61178104

  Manage Alerts
Collapse Summary General Information
Company Genmab A/S
DescriptionHuman bispecific antibody developed using DuoBody technology against 2 undisclosed inflammatory disease targets
Molecular Target Undisclosed
Mechanism of ActionBispecific antibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPhase I
Standard Indication Autoimmune (unspecified)
Indication DetailsTreat autoimmune disorders
Regulatory Designation
PartnerJohnson & Johnson

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today